Novartis targets next-wave allergy treatments with USD 2 billion Excellergy deal
Novartis has agreed to acquire biotech firm Excellergy in a deal valued at up to USD 2 billion, adding an early-stage anti-IgE therapy to its pipeline. The move strengthens its position in allergic disease treatments and signals continued investment in next-generation biologics.